Sign in

    Perry Mayo-Malasky

    Research Analyst at BTIG

    Perry Mayo-Malasky is an Equity Research Analyst specializing in financial institutions, with experience covering regional and national banks at leading firms. He began his career as an Equity Research Associate at BTIG LLC from 2020 to 2021, where he contributed to research coverage of diverse financial companies before moving to BofA Securities, Inc. as an Equity Research Analyst from 2021 to 2023, focusing on investment analysis for brokerage clients. Mayo-Malasky holds a doctorate degree from New York Medical College, completed in 2019, and has developed substantive expertise in finance during his career. His credentials include deep sector knowledge backed by advanced academic qualifications, offering valuable insight into the equities market.

    Perry Mayo-Malasky's questions to Lyra Therapeutics (LYRA) leadership

    Perry Mayo-Malasky's questions to Lyra Therapeutics (LYRA) leadership • Q1 2021

    Question

    Perry Mayo-Malasky of BTIG inquired about the preferred time point for the upcoming Phase 3 trial, given the efficacy seen at 24 weeks in the LANTERN study, and also asked about the progress of manufacturing capabilities for both the Phase 3 trial and future commercialization.

    Answer

    President and CEO Maria Palasis confirmed that a later time point, up to 24 weeks, would be proposed for the Phase 3 trial due to strong statistical significance (p=0.003 for three cardinal symptoms). She also stated that the technology transfer to their contract manufacturer is progressing well, emphasizing the partner's strength in automation which will be crucial for scaling up to meet the needs of millions of CRS patients upon commercialization.

    Ask Fintool Equity Research AI